This inventor holds 2 USPTO granted patents. Top assignee: Teijin Pharma Limited. Active years: 2009-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Walden Essex, GB (2009)
- Essex, GB (2010)
Company Filing History:
Years Active: 2009-2010
Title: Joelle Le: Innovator in Pharmaceutical Chemistry
Introduction
Joelle Le is a prominent inventor based in Essex, GB. She has made significant contributions to the field of pharmaceutical chemistry, particularly through her innovative work on pyrazolo[1,5-a]pyrimidine derivatives. With a total of 2 patents to her name, Joelle is recognized for her dedication to developing therapeutic agents for various medical conditions.
Latest Patents
Joelle's latest patents include the development of pyrazolo[1,5-a]pyrimidine derivatives that exhibit excellent MAPKAP-K2 inhibiting activity. These compounds, represented by formula I, and their pharmaceutically acceptable salts are expected to be effective in treating MAPKAP-K2 mediated disorders, such as inflammatory diseases, autoimmune diseases, destructive bone disorders, and cancer. Additionally, she has patented another set of pyrazolo[1,5-a]pyrimidine derivatives that demonstrate excellent kinase inhibiting activity. These drugs are anticipated to serve as therapeutic or prophylactic agents for disorders where protein kinases are implicated.
Career Highlights
Joelle Le is currently employed at Teijin Pharma Limited, where she continues to advance her research in pharmaceutical innovations. Her work is characterized by a strong focus on developing compounds that can address significant health challenges.
Collaborations
Joelle collaborates with esteemed colleagues, including Kenichiro Kataoka and Tomomi Kosugi, to further enhance her research and development efforts.
Conclusion
Joelle Le's contributions to pharmaceutical chemistry through her innovative patents highlight her role as a key inventor in the field. Her work promises to lead to significant advancements in the treatment of various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile